Directed therapy of subtypes of triple-negative breast cancer.
about
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerAngiogenesis and Antiangiogenesis in Triple-Negative Breast cancerWnt signaling in triple negative breast cancer is associated with metastasismicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancersAndrogen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Triple negative breast cancers have a reduced expression of DNA repair genesAntagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsAKAP3 correlates with triple negative status and disease free survival in breast cancer.Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.Methylation profile of triple-negative breast carcinomasP53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancerTargeting lactate transport suppresses in vivo breast tumour growthNovel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathwayMyeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerLeptin receptor maintains cancer stem-like properties in triple negative breast cancer cells.Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.Triple-negative breast cancer: making the most of a misnomer.Molecularly targeted therapies for metastatic triple-negative breast cancer.Concomitant resistance and early-breast cancer: should we change treatment strategies?cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code.Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women.The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches.The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
P2860
Q24202199-D2A05595-7EC0-43C0-88A9-37A4296F1F02Q28079013-DE3E0F3F-A204-456D-8150-37BB67AD6D70Q30597238-0A6D107A-1554-484B-8787-D52A4C6BF4B9Q33576814-D15EC4DB-E656-41BE-828D-6C6DA1E46C21Q33932665-978910B5-80BC-47DD-8EFA-5372317C832EQ34794035-4EAFD0F2-0D02-4B70-BA5B-D9A55234E6E6Q34813272-B5866BB7-C558-4100-8D17-4B4DC3FDCF4EQ35021758-22B07105-0197-40B8-B900-A41D0DC4422CQ35064200-B437DF76-FD1E-4CD7-82B9-565D7CF955C7Q35091400-F483663B-9F7F-4AD4-9B41-F0B629A1DB70Q35651216-12106DA0-1362-4FF2-A4BB-E7A76A7C6398Q35803623-ADFCBD47-4895-4180-9B32-B4AB59B13B33Q35873283-83C8F559-09B8-4F60-B9D2-62BF2E19E5A9Q36143153-249B8F29-F519-4595-96D3-725990A52B5CQ36289931-03956F5B-1E09-46C4-942F-037F2C0E3B52Q36315707-A0B2F27F-FF2B-4C63-A8CE-E2E8DE7B6E6AQ36326353-B577BA26-7C7F-43F7-9A27-643A91FF0F7BQ36343773-5FC8BB8B-5F25-4632-92F1-C7376AE08913Q36738895-5FBDEBF5-8AD1-47DD-AA76-38304F4EB970Q36751571-62427A93-8E87-456A-AFF7-8DA863A9D72DQ36991010-A949B197-2ACE-4242-A3F2-470F0BDBB3AFQ37350862-E638CABF-5749-496E-9E32-A4BCFD7D4506Q37536500-20CB9D6D-B2CB-47B0-9AF8-A32B585DDBABQ37542524-A0CFE8D5-4973-486C-9A42-9C06326A4EACQ37618855-BFEBC01A-6AAB-4BCE-86C4-B1C788808ED0Q37687445-60D703FE-2037-427E-8A1C-135654FFE543Q38004606-8175AF6E-8C83-451E-BBE7-F99C55B8F1E1Q38077472-5EB6D34E-0F84-4CE8-A15B-9E3C34046C97Q38171964-CE5B8A86-DE73-47EE-B76C-6CABCAEDC7A7Q38236096-BFE840F4-15FC-4010-960F-8B9427383D0CQ38895915-1633C0DE-66D8-46C8-BCFE-FB0FFB39D7EAQ39752527-D8753737-026F-404D-AF33-57DE865279C2Q41140262-45A70635-57D9-4366-AD9D-D4D4FDA3815EQ42275833-6965070F-CD3F-4EDE-867A-41EFB2A6580DQ42317506-C3B65F52-1478-416C-BB54-052D98488647Q45732305-4F8CF460-0DA1-4DC0-867F-0B847B8752EFQ46842412-65FB297F-52CE-442D-BDDD-30FFA569E12CQ47102297-B114D835-C81D-4940-BBBC-751D17CBC4BDQ47215852-AEA6A3C1-41D8-4286-A128-FC3572226A03
P2860
Directed therapy of subtypes of triple-negative breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Directed therapy of subtypes of triple-negative breast cancer.
@en
Directed therapy of subtypes of triple-negative breast cancer.
@nl
type
label
Directed therapy of subtypes of triple-negative breast cancer.
@en
Directed therapy of subtypes of triple-negative breast cancer.
@nl
prefLabel
Directed therapy of subtypes of triple-negative breast cancer.
@en
Directed therapy of subtypes of triple-negative breast cancer.
@nl
P1433
P1476
Directed therapy of subtypes of triple-negative breast cancer.
@en
P2093
Lisa A Carey
P356
10.1634/THEONCOLOGIST.2011-S1-71
P478
16 Suppl 1
P577
2011-01-01T00:00:00Z